|Day Low/High||18.29 / 18.87|
|52 Wk Low/High||15.68 / 31.81|
Knowing when to continue to fish or cut bait is something that develops over time in this space.
Here are updates on small biotech/biopharma names I have profiled before.
I think there is still upside left in a variety of smaller names especially if M&A activity picks up across the industry.
Markets continue to meander between being slightly up or slightly down as equities struggle for a direction after yesterday's big slide. New homes sales for the month of February were above expectations with the average selling price 10% above the s...
I hope we get a decent size market decline so I can add to some stakes in what I think are already undervalued biotech holdings.
The major indices have improved a tad since our last update. Biotech has shown some strength over the past two hours or so. There are two names to keep an eye on: T2 Biosystems has been strong so far in 2018, moving from around $4 to over $5 a shar...
Materials and technology names led the way down on the session.
It appears based on the futures that the market's rally will continue today, at least at the open. Personally, I think investors are becoming complacent given what could unfold in Greece over the next week. Everyone seems to be betting that Europe w...
Only one fund category (of 20) has beaten the S&P 500 over half a decade.